Saturday 17 October 2026
Export NTRA’s income statement to Excel — free account
Natera, Inc.
NTRA Healthcare Diagnostics & Research
Natera, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 35.9% from fiscal 2024. In the quarter to June 2026, revenue grew 37.7%, EPS grew 36.5%, free cash flow fell 174.0% and total debt was flat, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.
391.98
12.81
−3.16%
Follow NTRA
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
10.43 | 13.58 | 11.32 | 14.37 | |
P/FCF ratio |
208.20 | 287.05 | 270.78 | 461.93 | |
P/Operating CF |
371.85 | 423.90 | 704.46 | 709.82 | |
P/B ratio |
17.64 | 18.29 | 15.95 | 21.35 | |
Price to Tangible BV |
17.79 | 26.15 | 22.36 | 29.46 | |
EV/Sales |
10.11 | 13.27 | 11.03 | 14.10 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
110.18 | 142.18 | 130.69 | 167.23 | |
EV/FCF |
201.83 | 280.55 | 263.88 | 453.32 | |
Quick Ratio |
3.01 | 3.11 | 2.70 | 2.74 | |
Current Ratio |
3.27 | 3.39 | 2.96 | 3.00 | |
Net Debt/EBITDA |
11.02 | 114.60 | 13.75 | 18.52 | |
Debt/Assets |
4.41% | 3.35% | 3.07% | 3.02% | |
Debt/Equity |
0.06 | 0.05 | 0.05 | 0.04 | |
Asset Turnover |
1.24 | 1.14 | 1.15 | 1.23 | |
Operating CF/Net income |
(0.68) | 1.56 | (0.47) | (0.82) | |
Capex/Depreciation |
(2.17) | (2.56) | (1.09) | (2.99) | |
Interest Coverage |
(93.37) | (23.02) | (104.84) | (85.16) | |
Research and Development Expense of Revenue |
29.28% | 26.33% | 30.25% | 30.30% | |
Selling, General and Administrative Expense of Revenue |
52.10% | 43.77% | 47.07% | 43.47% | |
Intangible Assets out of Total Assets |
0.00 | 0.21 | 0.19 | 0.19 | |
Share Based Compensation of Revenue |
15.31% | 13.91% | 13.65% | 13.70% | |
Graham Net Nets |
0.04 | 0.03 | 0.03 | 0.02 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(1.42%) | (0.67%) | (0.82%) | (0.50%) | |
Free Cash Flow Yield |
0.48% | 0.35% | 0.37% | 0.22% | |
Revenue per Share |
4.32 | 4.87 | 4.92 | 5.25 | |
Operating CF per Share |
0.43 | 0.54 | 0.28 | 0.38 | |
Capex per Share |
(0.16) | (0.26) | (0.16) | (0.44) | |
Free Cash Flow per Share |
0.27 | 0.28 | 0.13 | (0.06) | |
Cash per Share |
7.60 | 7.87 | 7.69 | 7.62 | |
Shareholders Equity per Share |
9.13 | 12.52 | 12.54 | 12.71 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
9.13 | 12.52 | 12.54 | 12.71 | |
Free Cash Flow |
36.98 | 37.82 | 18.03 | (8.64) | |
Working Capital |
1,005.31 | 1,055.71 | 1,093.56 | 1,105.75 | |
Capital Expenditures |
(22.40) | (36.07) | (22.14) | (63.43) | |
Net Current Asset Value |
878.03 | 811.01 | 811.43 | 822.95 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.04 | 0.05 | 0.03 | 0.08 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
296.63 | 305.35 | 367.91 | 365.60 | |
Average Payables |
37.17 | 34.04 | 50.82 | 56.02 | |
Average Inventory |
56.68 | 56.59 | 60.54 | 67.31 | |
Average Assets |
1,706.21 | 2,029.54 | 2,173.38 | 2,207.28 | |
Average Common Equity |
1,065.36 | 1,453.92 | 1,506.85 | 1,533.84 |
Columns are period end dates